“The Second Health Care Technological Innovation Program-
From Idea to Commercialization”
An Executive Program for Biotechnology and Medical Device Entrepreneurs and Managers.
The Faculty of Management of Tel-Aviv University, the Israel Life Science Industry Organization (ILSI), The Center for Medicine in the Public Interest and International Institute for Biotechnology Entrepreneurship (a non-profit global contribution by Burrill & Company) are now holding the second program “Health Care Technological Innovation - From Idea to Commercialization.”
This program focuses on the critical elements in the formation, launch, and strategic and operational management of health-related technologies, with a particular focus on companies working in medicinal biotechnology, enabling technologies for life-science research, and medical devices used in human diagnosis and treatment.
We have had many excellent presentations focusing the value-driven reimbursement, personalized medicine as a platform for comparative effectiveness and the role of the Critical Path as a framework for demonstrating risks and benefits of products over the life of a product.
At the same time, Peter Pitts is featured in The Journal of Biolaw and Business Special Commemorative Edition published in honor of Israel's 60th anniversary. His article: "FDA and the Critical Path to 21st Century Medicine" is based on his presentation at the first CMPI sponsored seminar for Israeli life science startups in November 2007.
For the abstract and more info on The Journal go to www.biolawbusiness.com
PS I am also in Israel to see my son receive his beret after completing basic training in the IDF.
Here's the photo.
From Idea to Commercialization”
An Executive Program for Biotechnology and Medical Device Entrepreneurs and Managers.
The Faculty of Management of Tel-Aviv University, the Israel Life Science Industry Organization (ILSI), The Center for Medicine in the Public Interest and International Institute for Biotechnology Entrepreneurship (a non-profit global contribution by Burrill & Company) are now holding the second program “Health Care Technological Innovation - From Idea to Commercialization.”
This program focuses on the critical elements in the formation, launch, and strategic and operational management of health-related technologies, with a particular focus on companies working in medicinal biotechnology, enabling technologies for life-science research, and medical devices used in human diagnosis and treatment.
We have had many excellent presentations focusing the value-driven reimbursement, personalized medicine as a platform for comparative effectiveness and the role of the Critical Path as a framework for demonstrating risks and benefits of products over the life of a product.
At the same time, Peter Pitts is featured in The Journal of Biolaw and Business Special Commemorative Edition published in honor of Israel's 60th anniversary. His article: "FDA and the Critical Path to 21st Century Medicine" is based on his presentation at the first CMPI sponsored seminar for Israeli life science startups in November 2007.
For the abstract and more info on The Journal go to www.biolawbusiness.com
PS I am also in Israel to see my son receive his beret after completing basic training in the IDF.
Here's the photo.
